Brain stimulation test as a marker of thinking decline in Parkinson's
Tests a magnetic brain stimulation measure in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: TMS-related Measures as Biomarker of Cognitive Impairment in PD
Key facts
- Where
- Sterzing, Trento, and Trieste, ItalySee the 3 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with idiopathic Parkinson's disease, with or without memory and thinking problems, to study brain stimulation measures as markers of cognitive decline.
- Age
- Older than 18 years
- Sex
- All sexes can join
- Disease stage
- Idiopathic Parkinson's disease diagnosed by the latest MDS criteria. People with Parkinson's disease dementia cannot join.
- Earlier treatment
- Must be on stable and optimal antiparkinsonian therapy for at least four weeks. Cannot have had anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics or antidepressants in the last month.
Main reasons for not taking part
- Any other active neurological disease besides Parkinson's disease
- History of epilepsy or brain conditions that can cause seizures
- Implants such as a pacemaker, cochlear implant or brain electrodes for DBS
- Pregnancy or breastfeeding
- Dementia according to the latest MDS criteria for PDD
Read by machine on 12 November 2026.
Where in Italy
- UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto AdigeSterzing, ItalyContact: Viviana Versace, MDNot yet recruiting
- UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS)Trento, ItalyContact: Ruggero Bacchin, MDTaking people
- SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI)Trieste, ItalyContact: Paolo Manganotti, MDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Azienda Sanitaria Universitaria Integrata del Trentino
- Trial code
- NCT06835595
- Record updated
- 22 December 2025
- Original description
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline.Read full original descriptionShow less
Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)
The goal of the present study is to explore the diagnostic and prognostic value of neurophysiological biomarkers obtained through paired-pulse Transcranial Magnetic Stimulation (TMS) techniques in individuals affected by Parkinson's disease (PD) with and without cognitive decline.
The main questions it aims to answer are:
* TMS measures of cortical excitability are able to distinguish between PD patients cognitively normal, PD-Mild Cognitive Impairment (PD-MCI) and PD-Dementia (PD-D)? * TMS measures of cortical excitability are able to predict progression of PD patient cognitive status from cognitively normal to PD-MCI and PD-D?
Inclusion: Age > 18 years; Ability to undergo an extensive neuropsychological evaluation; Ability to sign informed consent for the study; Diagnosed with idiopathic PD according to the latest revision of the MDS criteria; On stable and optimal antiparkinsonian therapy for at least four weeks.
Exclusion: Presence of a cochlear implant, ferromagnetic brain device or near the site of brain stimulation, pacemaker, brain electrodes for DBS, electromechanical devices with IPG, or any other implantable stimulator, including peripheral ones; Treatment with anticholinesterase drugs, benzodiazepines, neuroleptics, anticholinergics, or antidepressants in the last month; Treatment with drugs that lower the seizure threshold (e.g., imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, cocaine, MDMA, ecstasy, phencyclidine, ketamine, gamma-hydroxybutyrate, alcohol, theophylline); Active cochlear pathology (especially if currently receiving ototoxic drugs, such as aminoglycoside antibiotics); Systemic diseases of significant severity, including cardiovascular and cerebrovascular conditions (e.g., active neoplasms requiring chemotherapy, or end-stage heart failure); Presence of any active neurological disease, in addition to PD; History of epilepsy; History of cerebrovascular, tumor-related, infectious, or metabolic brain conditions predisposing to seizures or causing symptomatic epilepsy; Dementia according to the latest revision of the MDS criteria for PDD; Pregnancy or breastfeeding; Alcoholism.